Abstract
It is now widely accepted that white adipose tissue (WAT) secretes a number of peptide hormones, including leptin, several cytokines, adipsin and acylation-stimulating protein (ASP), angiotensinogen, plasminogen activator inhibitor-1 (PAI-1), adiponectin, resistin etc., and also produces steroids hormones. This newly discovered secretory function has shifted our view of WAT, which is no longer considered only an energy storage tissue but a major endocrine organ, at the heart of a complex network influencing energy homeostasis, glucose and lipid metabolism, vascular homeostasis, immune response and even reproduction. Virtually all known adipose secreted proteins are dysregulated when the WAT mass is markedly altered, either increased in the obese state or decreased in lipoatrophy. This strongly implicates adiposesecreted products in the ethiopathology and/or complications of both obesity and cachexia. This review discusses the physiological relevance of adipose secretion by focusing on protein and steroid hormones. Regulation of WAT secretion by the major regulatory factors impinging on the adipocytes, i.e. insulin, glucocorticoids, catecholamines and thiazolidinediones (TZD) will be addressed. The rationale for therapeutic strategies aimed at compensating adverse effects resulting from overproduction or lack of a specific adipose secretory product will be discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Rosen E.D., Spiegelman B.M. Ppargamma: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 2001, 276: 37731–37734.
Mohamed-Ali V., Pinkney J.H., Coppack S.W. Adipose tissue as an endocrine and paracrine organ. Int. J. Obes. Relat. Metab. Disord. 1998, 22: 1145-1158.
Trayhurn P., Beattie J.H. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc. Nutr. Soc. 2001, 60: 329–339.
Fruhbeck G., Gomez-Ambrosi J., Muruzabal F.J., Burrell M.A. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am. J. Physiol. Endocrinol. Metab. 2001, 280: E827–E847.
Björntörp P. Endocrine abnormalities of obesity. Metabolism 1995, 44: 21–23.
Masuzaki H., Paterson J., Shinyama H. et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294: 2166–2170.
Cassis L.A., Saye J., Peach M.J. Location and regulation of rat angiotensinogen messenger RNA. Hypertension 1988, 11: 591–596.
Frederich R.C.J., Kahn B.B., Peach M.J., Flier J.S. Tissuespecific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992, 19: 339–344.
Massiera F., Bloch-Faure M., Ceiler D. et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 2001, 15: 2727–2729.
Eriksson P., Reynisdottir S., Lonnqvist F., Stemme V., Hamsten A., Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998, 41: 65–71.
Samad F., Uysal K.T., Wiesbrock S.M., Pandey M., Hotamisligil G.S., Loskutoff D.J. Tumor necrosis factor-a is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc. Natl. Acad. Sci. USA 1999, 96: 6902–6907.
Alessi M.C., Bastelica D., Morange P. et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000, 49: 1374–1380.
Kersten S., Mandard S., Tan N.S. et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 2000, 275: 28488–28493.
Yoon J.C., Chickering T.W., Rosen E.D. et al. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol. Cell Biol. 2000, 20 (14): 5343–5349.
Cook K.S., Min H.Y., Johnson D. et al. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science 1987, 237: 402–405.
Coppack S.W. Pro-inflammatory cytokines and adipose tissue. Proc. Nutr. Soc. 2001, 60: 349–356.
Murray I., Sniderman A.D., Havel P.J., Cianflone K. Acylation stimulating protein (ASP) deficiency alters postprandial and adipose tissue metabolism in male mice. J. Biol. Chem. 1999, 274: 36219–36225.
Saleh J., Blevins J.E., Havel P.J., Barrett J.A., Gietzen D. W., Cianflone K. Acylation stimulating protein (ASP) acute effects on postprandial lipemia and food intake in rodents. Int. J. Obes. Relat. Metab. Disord. 2001, 25: 705–713.
Hotamisligil G.S., Spiegelman B.M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994, 43: 1271–1278.
Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259: 87–91.
Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389: 610–614.
Singh A.H., Liu S., Crombie D.L. et al. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol. Pharmacol. 2001, 59: 765–773.
Kern P.A., Ranganathan S., Li C., Wood L., Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab 2001, 280: E745–E751.
Bastard J.P., Maachi M., Van Nhieu J.T. et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J. Clin. Endocrinol. Metab. 2002, 87: 2084–2089.
Wallenius V., Wallenius K., Ahren B. et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 2002, 8: 75–79.
Wallenius K., Wallenius V., Sunter D., Dickson S.L., Jansson J.O. Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem. Biophys. Res. Commun. 2002, 293: 560–565.
Campfield L.A., Smith F.J., Burn P. The OB protein (leptin) pathway—a link between adipose tissue mass and central neural networks. Horm. Metab. Res. 1996, 28: 619–632.
Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395: 763–770.
Ahima R.S., Flier J.S. Leptin. Annu. Rev. Physiol. 2000, 62: 413–437.
Rayner D.V., Trayhurn P. Regulation of leptin production: sympathetic nervous system interactions. J. Mol. Med. 2001, 79: 8–20.
Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue [published erratum appears in Nature 1995, 374 (6521): 479. Nature 1994, 372: 425–432.
Tartaglia L.A., Dembski M., Weng X. et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995, 83: 1263–1271.
Farooqi I.S., Jebb S.A., Langmack G. et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 1999, 341: 879–884.
Clement K., Vaisse C., Lahlou N. et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998, 392: 398–401.
Heymsfield S.B., Greenberg A.S., Fujioka K. et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999, 282: 1568–1575.
Ahima R.S., Prabakaran D., Mantzoros C. et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996, 382: 250–252.
Bluher M., Michael M.D., Peroni O.D. et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev. Cell 2002, 3: 25–38.
Trayhurn P., Hoggard N., Mercer J.G., Rayner D.V. Leptin: fundamental aspects. Int. J. Obes. Relat. Metab. Disord. 1999, 23 (1): 22–28.
Mark A.L., Correia M.L., Rahmouni K., Haynes W.G. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J. Hypertens. 2002, 20: 1245–1250.
Berg A.H., Combs T.P., Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 2002, 13: 84–89.
Maeda N., Shimomura I., Kishida K. et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002, 8: 731–737.
Matsuda M., Shimomura I., Sata M. et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipovascular axis. J. Biol. Chem. 2002, 277: 37487–37491.
Kubota N., Terauchi Y., Yamauchi T. et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 2002, 277: 25863–25866.
Ma K., Cabrero A., Saha P.K. et al. Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J. Biol. Chem. 2002, 277: 34658–34661.
Yamauchi T., Kamon J., Waki H. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001, 7: 941–946.
Steppan C.M., Bailey S.T., Bhat S. et al. The hormone resistin links obesity to diabetes. Nature 2001, 409: 307–312.
Kim K.H., Lee K., Moon Y.S., Sul H.S. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J. Biol. Chem. 2001, 276: 11252–11256.
Steppan C.M., Lazar M.A. Resistin and obesity-associated insulin resistance. Trends Endocrinol. Metab. 2002, 13: 18–23.
Way J.M., Gorgun C.Z., Tong Q. et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor? agonists. J. Biol. Chem. 2001, 276: 25651–25653.
Le Lay S., Boucher J., Rey A. et al. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem. Biophys. Res. Commun. 2001, 289: 564–567.
Savage D.B., Sewter C.P., Klenk E.S. et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001, 50: 2199–2202.
Abel E.D., Peroni O., Kim J.K. et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001, 409: 729–733.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guerre-Millo, M. Adipose tissue hormones. J Endocrinol Invest 25, 855–861 (2002). https://doi.org/10.1007/BF03344048
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03344048